

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
5508303.pn.	1

Database: US Patents Full-Text Database ▲
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins ▼

Search: L4 ▲
▼ Refine Search

Recall Text Clear

Search History

DATE: Monday, September 30, 2002 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT; PLUR=YES; OP=OR

L4 5508303.pn. 1 L4

DB=JPAB,EPAB,DWPI; PLUR=YES; OP=OR

L3 prostaglandin and (EP4 EP-4)and hair 6 L3

DB=USPT; PLUR=YES; OP=OR

L2 L1 and hair 0 L2

L1 prostaglandin and (EP4 EP-4) 24 L1

END OF SEARCH HISTORY

L14 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002 ACS

AN 2001:935627 CAPLUS

DN 136:48819

TI Methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists

IN Roders, Kathleen E.; Dizerega, Gere S.

PA University of Southern California, USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K007-14

ICS A61K038-06; A61K038-07; A61K038-08; A61P017-14

CC 2-10 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098325	A1	20011227	WO 2000-US32340	20001127
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-212608P P 20000619

OS MARPAT 136:48819

AB The present invention provides improved methods, kits, and pharmaceutical compns. for treating and preventing alopecia in a subject in need thereof by administering an effective amt. of angiotensinogen, angiotensin I

(AI),

AI analogs, AI fragments and analogs thereof, angiotensin II (AII), AII analogs, AII fragments or analogs thereof or AII AT2 type 2 receptor agonists to the subject. The method further comprises treating the subject with an effective amt. of another compd. for treating or preventing alopecia, selected from the group consisting of minoxidol, keratinocyte growth factor, fibroblast growth factor, epidermal growth factor, butyric acid and its derivs., ammonium trichloro(dioxyethylene-0,0') tellurate, interleukin 1, prostaglandin E2, cyclosporine A, corticosteroids and calcitriol.

ST alopecia treatment angiotensinogen angiotensin AT2 receptor agonist

IT Alopecia

(adrenergic; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Diabetes mellitus

(alopecia assocd. with; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs

and

fragments and AT2 receptor agonists)

IT Alopecia

(anagen effluvium; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Alopecia

(areata; methods for treating and preventing alopecia using

angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Alopecia
(arthropathica; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Nutrition, animal
(deficiencies, alopecia assocd. with; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Disease, animal
(deficiency, alopecia assocd. with; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Metabolism, animal
(disorder, alopecia assocd. with; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Alopecia
(erythrodermica; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Skin, disease
(genodermatoses with pathol. cornification disorders; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT **Hair** preparations
(growth stimulants; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Vitamins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hypervitaminosis ;; alopecia assocd. with; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Skin, disease
(ichthyosis; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Keratosis
(methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Corticosteroids, biological studies
Interleukin 1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists in combination with other agents)

IT Human
(methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Mammary gland
(neoplasm, inhibitors ;; alopecia from; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT Skin, disease
(palmoplantar pustulosis; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Alopecia
(para-alopecia; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Alopecia
(pustulosa; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Alopecia
(telogen effluvium; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Alopecia
(traumatic; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Angiotensin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type AT2; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT Alopecia
(vulgaris; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT 50-18-0, Cyclophosphamide 23214-92-8, Doxorubicin
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alopecia from; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT 7440-66-6, Zinc, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deficiency, alopecia assocd. with; methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists)

IT 9041-90-1, Angiotensin I 9041-90-1D, Angiotensin I, analogs and fragments 11002-13-4, Angiotensinogen (protein renin substrate) 11128-99-7, Angiotensin II 11128-99-7D, Angiotensin II, analogs and fragments
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

IT 107-92-6, Butyric acid, biological studies 107-92-6D, Butyric acid, derivs. 363-24-6, Prostaglandin E2 32222-06-3, Calcitriol 59865-13-3, Cyclosporine A 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 106566-58-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, analogs and fragments and AT2 receptor agonists)

agonists in combination with other agents)

IT 53-73-6, Asn-Arg-Val-Tyr-Val-His-Pro-Phe peptide+ 58-49-1,
 Asp-Arg-Val-Tyr-Val-His-Pro-Phe peptide+ 484-42-4, Asp-Arg-Val-Tyr-Ile-
 His-Pro-Phe-His-Leu peptide+ 4474-91-3, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
 peptide+ 4474-91-3D, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe peptide+,
 phosphorylated 13602-53-4, Arg-Val-Tyr-Ile-His-Pro-Phe peptide+
 13761-29-0, Asp-Arg-Ala-Tyr-Ile-His-Pro-Phe peptide+ 19729-16-9,
 Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe peptide+ 22684-02-2,
 Asp-Arg-Val-Tyr-Ile-His-Ala-Phe peptide+ 23025-68-5,
 Val-Tyr-Ile-His-Pro-Phe peptide+ 25061-67-0,
 Asp-Arg-Val-Tyr-Ile-His-Pro-
 Tyr peptide+ 31025-44-2, His-Pro-Phe peptide+ 34233-50-6,
 Ile-His-Pro-Phe peptide+ 35463-59-3, Asp-Arg-Val-Tyr-Ile-His-Pro-Ile
 peptide+ 37578-26-0 37779-43-4, Asp-Arg-Val-Tyr-Nle-His-Pro-Phe
 peptide+ 39759-50-7, Asp-Arg-Val-Tyr-Leu-His-Pro-Phe peptide+
 42061-45-0, Asp-Arg-Val peptide+ 47896-63-9, Asp-Arg-Val-Tyr-Ile-His
 peptide+ 47917-67-9, Asp-Arg-Val-Tyr-Ile-Arg-Pro-Phe peptide+
 51833-74-0, Pro-Arg-Val-Tyr-Ile-His-Pro-Phe peptide+ 51833-78-4,
 Asp-Arg-Val-Tyr-Ile-His-Pro peptide+ 51865-62-4,
 Gly-Arg-Val-Tyr-Ile-His-
 Pro-Phe peptide+ 52530-60-6, Tyr-Ile-His-Pro-Phe peptide+ 52580-29-7,
 Asp-Arg-Val-Tyr peptide+ 58442-64-1, Asp-Arg-Val-Tyr-Ile peptide+
 72007-47-7, Ala-Pro-Gly-Asp-Arg-Ile-Tyr-Val-His-Pro-Phe peptide+
 85734-57-2, Asp-Lys-Val-Tyr-Ile-His-Pro-Phe peptide+ 85734-58-3,
 Asp-Orn-Val-Tyr-Ile-His-Pro-Phe peptide+ 90937-05-6 113851-71-1,
 Arg-Val-Tyr-Ile-His-Pro peptide+ 122483-84-5, Val-Tyr-Ile-His-Pro
 peptide+ 139123-03-8, Glu-Arg-Val-Tyr-Ile-His-Pro-Phe peptide+
 149475-39-8, Asp-Arg-Val-Thr-Ile-His-Pro-Phe peptide+ 209164-95-4,
 Arg-Val-Tyr-Gly-His-Pro-Phe peptide+ 209164-96-5, Arg-Val-Tyr-Ala-His-
 Pro-Phe peptide+ 209165-00-4, Asp-Arg-Nle-Tyr-Ile-His-Pro-Phe peptide+
 210982-24-4, Arg-Nle-Tyr-Ile-His-Pro-Phe peptide+ 210982-26-6,
 Arg-Val-Tyr-Nle-His-Pro-Phe peptide+ 227803-63-6, Asp-Arg-Nle-Tyr-Ile-
 His-Pro peptide+ 236744-96-0, Asp-Arg-Pro-Tyr-Ile-His-Pro peptide+
 236744-97-1, Asp-Arg-Lys-Tyr-Ile-His-Pro peptide+ 243991-39-1,
 Asp-Arg-Val-Ser-Tyr-Ile-His-Pro-Phe peptide+ 246513-38-2,
 Asp-Arg-Val-Ala-Ile-His-Pro peptide+ 254974-72-6, Asp-Arg-Pro-Ala-Ile-
 His-Pro peptide+ 292601-37-7 292601-38-8, Arg-Val-Ala-Ile-His-Pro-Phe
 peptide+ 292601-39-9, Arg-Val-Tyr-Nle-Leu-His-Pro-Phe peptide+
 380913-81-5 381263-77-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods for treating and preventing alopecia using angiotensinogen,
 angiotensin I, angiotensin II, their analogs and fragments and AT2
 receptor agonists)

IT 38304-91-5, Minoxidil 148348-15-6, Keratinocyte growth factors
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods for treating and preventing alopecia using angiotensinogen,
 angiotensin I, angiotensin II, their analogs and fragments and AT2
 receptor agonists in combination with other agents)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Anon; PATENT ABSTRACTS OF JAPAN 1998, V1998(01)
- (2) Board Of Regents; US 5804445 A 1998 CAPLUS
- (3) Daly; US 5567679 A 1996 CAPLUS
- (4) Honen Corp; JP 09249535 A 1997 CAPLUS
- (5) LI LI Wang, M; Clinical observations of chemotherapy combining with ang II
 in advanced lung cancer 1996
- (6) LI LI Wang, M; Zhongguo Zhongliu Linchuang 1995, V22, P791
- (7) Rodgers; JOURNAL OF BURN CARE REHABILITATION 1997, V18, P381 MEDLINE

- (8) Steckerlings; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION 1996, V229, P329
- (9) The Trustees Of The University Of Pennsylvania; US 5753226 A 1998 CAPLUS

L14 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2002 ACS

AN 1997:131617 CAPLUS

DN 126:152773

TI Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its **hair** growth-stimulating effect

AU Michelet, Jean-Francois; Commo, Stephane; Billoni, Nelly; Mahe, Yann F.; Bernard, Bruno A.

CS Hair Biology Research Group, L'OREAL, Clichy, 92583, Fr.

SO Journal of Investigative Dermatology (1997), 108(2), 205-209

CODEN: JIDEAE; ISSN: 0022-202X

PB Blackwell

DT Journal

LA English

CC 1-12 (Pharmacology)

AB Nonsteroidal anti-inflammatory drugs induce **hair** loss in vivo. These drugs are inhibitors of both the cytoprotective isoform of prostaglandin endoperoxide synthase-1 (PGHS-1) and of the inducible form (PGHS-2). Immunohistochem. staining showed that PGHS-1 is the main isoform present in the dermal papilla from normal human **hair** follicles (either anagen or catagen), whereas PGHS-2 was only faintly and exclusively expressed in anagen dermal papilla. Thus, PGHS-1 might be

the primary target of the **hair** growth-inhibitory effects of nonsteroidal inflammation inhibitors. It was thus speculated that activation of PGHS-1 might be a mechanism by which minoxidil stimulates **hair** growth in vivo. It is shown here that minoxidil is a potent activator of purified PGHS-1, as demonstrated by increased O consumption and PGE2 prodn. This activation was also evidenced by increased PGE2 prodn. by BALB/c 3T3 fibroblasts and by human dermal papilla fibroblasts in culture. Minoxidil and its derivs. may have a cytoprotective activity in vivo.

ST minoxidil **hair** growth prostaglandin synthase

IT **Hair**

(follicle; minoxidil activation of prostaglandin synthase-1 in human)

IT Fibroblast

(minoxidil activation of prostaglandin synthase-1 in)

IT **Hair**

(minoxidil activation of prostaglandin synthase-1 in relation to

growth

of human)

IT 9055-65-6, Prostaglandin synthase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(1; minoxidil activation of prostaglandin synthase-1 in relation to **hair** growth)

IT 363-24-6, PGE2

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(minoxidil stimulation of PGE2 formation in relation to human **hair** growth)

IT 38304-91-5, Minoxidil

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); BIOL (Biological study)

(prostaglandin synthase-1 activation by minoxidil in relation to human

hair growth)

L14 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2002 ACS

AN 1996:612794 CAPLUS

DN 125:245679

TI Procedure for diagnosing and/or following the development of a **hair** disorder and/or measuring the effectiveness of a treatment for a **hair** disorder

IN Mahe, Yann; Buan, Bruno; Loussouarn, Genevieve

PA Oreal S. A., Fr.

SO Fr. Demande, 17 pp.

CODEN: FRXXBL

DT Patent

LA French

IC ICM G01N033-48

ICS G01N033-68; G01N033-88

CC 15-1 (Immunochemistry)

Section cross-reference(s): 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2730811	A1	19960823	FR 1995-1881	19950217
	FR 2730811	B1	19970321		
AB	The title procedure, which is useful in the early diagnosis and treatment of alopecia, involves the isolation of .gtoreq.1 hair follicle from a human or animal, incubation of the hair follicle(s) in an appropriate culture medium for a specific time, and detn. of .gtoreq.1 inflammation mediator related to the hair disorder. The inflammation mediator is chosen preferably from the interleukins or prostaglandins and esp. interleukin 1.alpha. or PGE2. Early identification of the hyperprodn. of inflammation mediators in hair follicles permits one to predict the risk of developing alopecia and to begin therapy to limit the development of the alopecia.				
ST	hair disorder inflammation mediator detn follicle; alopecia diagnosis therapy interleukin prostaglandin detn				
IT	Hair (disorder; inflammation mediator detn. in hair follicle culture for diagnosis and/or treatment of hair disorders)				
IT	Alopecia Animal tissue culture Inflammation (inflammation mediator detn. in hair follicle culture for diagnosis and/or treatment of hair disorders)				
IT	Lymphokines and Cytokines Prostaglandins RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study) (inflammation mediator detn. in hair follicle culture for diagnosis and/or treatment of hair disorders)				
IT	Lymphokines and Cytokines RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study) (chemokines, inflammation mediator detn. in hair follicle culture for diagnosis and/or treatment of hair disorders)				
IT	Hair (follicle, inflammation mediator detn. in hair follicle culture for diagnosis and/or treatment of hair disorders)				
IT	Lymphokines and Cytokines RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)				

(interleukin 1.alpha., inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (interleukin 1.beta., inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (interleukin 6, inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (interleukin 8, inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (interleukins, inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (monocyte chemoattractant protein 1, inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (tumor necrosis factor-.alpha., inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT Lymphokines and Cytokines
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (tumor necrosis factor-.beta., inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

IT **363-24-6**, Prostaglandin E2 506-32-1, Arachidonic acid
 71160-24-2, Leukotriene B4
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
 (inflammation mediator detn. in **hair** follicle culture for diagnosis and/or treatment of **hair** disorders)

L14 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2002 ACS
AN 1997:131617 CAPLUS
DN 126:152773
TI Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a
possible explanation for its **hair** growth-stimulating effect
AU Michelet, Jean-Francois; Commo, Stephane; Billoni, Nelly; Mahe, Yann F.;
Bernard, Bruno A.
CS Hair Biology Research Group, L'OREAL, Clichy, 92583, Fr.
SO Journal of Investigative Dermatology (1997), 108(2), 205-209
CODEN: JIDEAE; ISSN: 0022-202X
PB Blackwell
DT Journal
LA English

L14 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2002 ACS

AN 1996:612794 CAPLUS

DN 125:245679

TI Procedure for diagnosing and/or following the development of a
hair disorder and/or measuring the effectiveness of a treatment
for a **hair** disorder

IN Mahe, Yann; Buan, Bruno; Loussouarn, Genevieve

PA Oreal S. A., Fr.

SO Fr. Demande, 17 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	FR 2730811	A1	19960823	FR 1995-1881	19950217
	FR 2730811	B1	19970321		

L14 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002 ACS
AN 2001:935627 CAPLUS
DN 136:48819
TI Methods for treating and preventing alopecia using angiotensinogen,
angiotensin I, angiotensin II, their analogs and fragments and AT2
receptor agonists
IN Roders, Kathleen E.; Dizerega, Gere S.
PA University of Southern California, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

L14 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002 ACS

AN 2001:935627 CAPLUS

DN 136:48819

TI Methods for treating and preventing alopecia using angiotensinogen, angiotensin I, angiotensin II, their analogs and fragments and AT2 receptor agonists

IN Roders, Kathleen E.; Dizerega, Gere S.

PA University of Southern California, USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098325	A1	20011227	WO 2000-US32340	20001127
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-212608P P 20000619

OS MARPAT 136:48819

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2001 年 10 月 4 日 (04.10.2001)

PCT

(10) 国際公開番号
WO 01/72268 A1

- (51) 国際特許分類: A61K 7/06, A61P 17/14 D-2 Kanagawa (JP). 林 亮司 (HAYASHI, Ryoji) [JP/JP]; 千 251-0033 神奈川県藤沢市片瀬山 3-13-9 Kanagawa (JP). 森 岳志 (MORI, Takeshi) [JP/JP]; 千 222-0002 神奈川県横浜市港北区師岡町 343-23 Kanagawa (JP). 磯ヶ谷 昌文 (ISOGAYA, Masafumi) [JP/JP]; 千 245-0016 神奈川県横浜市泉区和泉町 3989-7 Kanagawa (JP).
- (21) 国際出願番号: PCT/JP01/02756
- (22) 国際出願日: 2001 年 3 月 30 日 (30.03.2001)
- (25) 国際出願の言語: 日本語
- (26) 国際公開の言語: 日本語
- (30) 優先権データ: 特願 2000-97542 2000 年 3 月 31 日 (31.03.2000) JP (81) 指定国 (国内): AU, CA, CN, JP, KR, US.
- (71) 出願人 (米国を除く全ての指定国について): 東レ株式会社 (TORAY INDUSTRIES, INC.) [JP/JP]; 千 103-8666 東京都中央区日本橋室町 2 丁目 2 番 1 号 Tokyo (JP). (84) 指定国 (広域): ヨーロッパ特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (72) 発明者; および
- (75) 発明者/出願人 (米国についてのみ): 熊谷洋紀 (KUMAGAI, Hiroki) [JP/JP]; 千 248-0034 神奈川県鎌倉市津西 2-1-20 L302 Kanagawa (JP). 山田尚弘 (YAMADA, Naohiro) [JP/JP]; 千 248-0034 神奈川県鎌倉市津西 1-26-17
- 添付公開書類:
— 国際調査報告書
- 2 文字コード及び他の略語については、定期発行される各 PCT ガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: HAIR GROWTH OR HAIR FORMATION CONTROLLING AGENTS

(54) 発明の名称: 育毛あるいは発毛調節剤

(57) Abstract: Agents controlling hair growth or hair formation which have an excellent effect of controlling hair growth or hair formation while showing little side effect. These agents contain as the active ingredient a prostaglandin EP4 receptor agonist.

(57) 要約:

優れた育毛あるいは発毛調節活性を有し、副作用が少ない育毛あるいは発毛調節剤が開示されている。本発明の育毛あるいは発毛調節剤は、プロスタグランジン EP4 受容体作用薬を有効成分として含有する。

WO 01/72268 A1